Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +4 vs. previous quarter
- 27
- 13F valueReported value at the end of Q2 2026
- $32.6M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding XLO, Q2 2026
No superinvestor reported holding XLO at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Xilio Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 (view filing) | Mar 26 | 4 days | Shannon James SamuelDirector | PPurchase | +5.00K | $8.79 | +$44.0K | +100.0%10.0K after | |
| Feb 17, 2026 (view filing) | Feb 13 | 4 days | Gilead Sciences, Inc.10% Owner | PPurchase | +3.74M | $0.53 | +$1.98M | –40.4M after | Derivative |
| Jan 5, 2026 (view filing) | Jan 2 | 3 days | Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | SSale | −1.83K | $0.64 | −$1.17K | −22.3%6.37K after | 10b5-1 |
| Jan 5, 2026 (view filing) | Jan 2 | 3 days | Frankenfield Christopher JamesChief Financial Officer | SSale | −7.03K | $0.64 | −$4.50K | −22.1%24.8K after | 10b5-1 |
| Jun 18, 2025 (view filing) | Jun 16-17 | 2 days | Shannon James SamuelDirector | PPurchase | +70.0K | $0.69 | +$48.3K | New position70.0K after | 2 lots |
| Jun 18, 2025 (view filing) | Jun 16 | 2 days | Russo RenePRESIDENT AND CEO | PPurchase | +36.3K | $0.68 | +$24.7K | +14.8%281.2K after | |
| Jun 6, 2025 (view filing) | Jun 5 | 1 day | Gilead Sciences, Inc.10% Owner | PPurchase | +53.3M | – | – | –13.3M after | Derivative4 lots |
| Jan 3, 2025 (view filing) | Jan 2 | 1 day | Frankenfield Christopher JamesChief Financial Officer | SSale | −6.95K | $0.98 | −$6.81K | −35.9%12.4K after | 10b5-1 |
| Jan 3, 2025 (view filing) | Jan 2 | 1 day | Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | SSale | −1.80K | $0.98 | −$1.77K | −36.1%3.20K after | 10b5-1 |
| Dec 19, 2024 (view filing) | Dec 18 | 1 day | Gilead Sciences, Inc.10% Owner | PPurchase | +1.76M | $1.04 | +$1.83M | +24.0%9.11M after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Xilio Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 664,021 | $6.36M | 0.38% | 00.0% | Unchanged |
| Gilead Sciences, Inc. | 650,389 | $6.23M | 0.38% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 592,300 | $5.67M | 0.11% | +592,300 | New |
| Frazier Life Sciences Management, L.P. | 422,505 | $4.05M | 0.09% | 00.0% | Unchanged |
| Stonepine Capital Management, LLC | 225,994 | $2.17M | 1.65% | +161,832+252.2% | Added |
| Vanguard Capital Management LLC | 178,517 | $1.71M | 0.00% | +54,857+44.4% | Added |
| Sio Capital Management, LLC | 152,464 | $1.46M | 0.25% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 111,541 | $1.07M | 0.00% | +111,541 | New |
| Merck & Co., Inc. | 105,982 | $1.02M | 0.19% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 64,153 | $614.6K | 0.00% | +14,587+29.4% | Added |